News Release

<< Back

Sunesis Pharmaceuticals to Present at 28th Annual Credit Suisse Healthcare Conference

11/08/19

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that Willie Quinn, Chief Financial Officer and Senior Vice President, Finance and Corporate Development of Sunesis, will present at the 28th Annual Credit Suisse Healthcare Conference on Wednesday, November 13, 2019 at 11:30 AM Mountain Time in Scottsdale, Arizona.

A live webcast of the presentation will be available on the Sunesis website at http://ir.sunesis.com.  A replay will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company developing novel targeted inhibitors for the treatment of hematologic and solid cancers. Sunesis has built an experienced drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase inhibitor pipeline, with an emphasis on its oral non-covalent BTK inhibitor vecabrutinib. Vecabrutinib is currently being evaluated in a Phase 1b/2 study in adults with chronic lymphocytic leukemia and other B-cell malignancies that have progressed after prior therapies.

For additional information on Sunesis, please visit www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.

Investor and Media Inquiries:
Maeve Conneighton     Willie Quinn
Argot Partners     Sunesis Pharmaceuticals Inc.
212-600-1902     650-266-3716

SNSS logo.PNG

Source: Sunesis Pharmaceuticals, Inc.